CTIM-22. NIVOLUMAB AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA; T-CELL REACTIVITY AGAINST AUTOLOGOUS TUMOR CELLS

Authors: Simone Maarup, Signe Skadborg, Annie Borch, Arianna Draghi, Benedikte Hasselbalch, Olga Østrup, David Scheie, Jane Skjoeth-Rasmussen, Ian Law, Inge Marie Svane, Hans Poulsen, Sine Hadrup, Ulrik Lassen

Published: 2021-11-18

DOI: 10.1093/neuonc/noab196.214

Source: Full article

CTIM-22. NIVOLUMAB AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA; T-CELL REACTIVITY AGAINST AUTOLOGOUS TUMOR CELLS

Abstract